• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    10/17/23 5:31:47 PM ET
    $ATHX
    $BIO
    $BIOC
    $EIGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ATHX alert in real time by email

    Gainers

    • Biocept (NASDAQ:BIOC) shares moved upwards by 109.4% to $1.07 during Tuesday's after-market session. Trading volume for this security closed at 4.8 million, accounting for 264.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares moved upwards by 31.44% to $0.4. At the close, Intelligent Bio Solutions's trading volume reached 2.0 million shares. This is 1402.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 million.
    • RVL Pharmaceuticals (NASDAQ:RVLP) stock rose 17.45% to $0.06. RVL Pharmaceuticals's trading volume hit 18.7 million shares by close, accounting for 104.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.6 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares rose 14.94% to $0.89. The market value of their outstanding shares is at $10.4 million.
    • Exagen (NASDAQ:XGN) shares moved upwards by 8.92% to $1.83. The company's market cap stands at $30.8 million.
    • PaxMedica (NASDAQ:PXMD) stock rose 7.61% to $0.26. The market value of their outstanding shares is at $4.4 million.

    Losers

    • Athersys (NASDAQ:ATHX) shares fell 43.9% to $0.06 during Tuesday's after-market session. Athersys's trading volume hit 45.3 million shares by close, accounting for 2010.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.5 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock fell 9.67% to $0.27. The company's market cap stands at $12.0 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) shares declined by 7.53% to $2.95. The market value of their outstanding shares is at $1.6 million.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) shares decreased by 6.6% to $34.4. The market value of their outstanding shares is at $2.4 billion.
    • Bio-Rad Laboratories (NYSE:BIO) stock fell 5.59% to $322.0. The market value of their outstanding shares is at $9.3 billion.
    • Inspire Veterinary (NASDAQ:IVP) stock fell 5.49% to $0.86. The company's market cap stands at $10.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATHX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHX
    $BIO
    $BIOC
    $EIGR

    CompanyDatePrice TargetRatingAnalyst
    Ultragenyx Pharmaceutical Inc.
    $RARE
    3/24/2026$25.00Buy → Neutral
    Goldman
    Ultragenyx Pharmaceutical Inc.
    $RARE
    10/20/2025$65.00Overweight
    Wells Fargo
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Ultragenyx Pharmaceutical Inc.
    $RARE
    7/28/2025$80.00Buy
    H.C. Wainwright
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    Ultragenyx Pharmaceutical Inc.
    $RARE
    5/28/2025Outperform
    William Blair
    Bio-Rad Laboratories Inc.
    $BIO
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ATHX
    $BIO
    $BIOC
    $EIGR
    SEC Filings

    View All

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    4/2/26 8:45:09 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    3/30/26 8:45:08 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Ultragenyx Pharmaceutical Inc.

    DEFA14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    3/27/26 4:30:56 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ultragenyx Pharma downgraded by Goldman with a new price target

    Goldman downgraded Ultragenyx Pharma from Buy to Neutral and set a new price target of $25.00

    3/24/26 8:28:47 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

    Wells Fargo initiated coverage of Ultragenyx Pharma with a rating of Overweight and set a new price target of $65.00

    10/20/25 8:02:57 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/19/24 7:24:38 PM ET
    $XGN
    Medical Specialities
    Health Care

    President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/18/24 6:32:33 PM ET
    $XGN
    Medical Specialities
    Health Care

    Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    5/16/24 8:02:50 PM ET
    $XGN
    Medical Specialities
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

    If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration and early death PDUFA action date set for September 19, 2026 NOVATO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the resubmitted Biologics License Application (BLA) seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome Type A (MPS IIIA). The FDA set a Prescription Dru

    4/2/26 8:30:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

    Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its initial clinical Cut-off Study supporting the Company's FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The clinical Cu

    4/2/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

    NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX016, an investigational small molecule prodrug of sialic acid (SA) being evaluated as a substrate replacement therapy for GNE myopathy (GNEM). GNEM is a rare, severely debilitating, inherited neuromuscular disorder caused by mutations in the GNE gene that lead to deficient SA production. The UX016 program is externally funded by a patient group through clinical proof-of-concept, including a Phase 1/2 study expected to begin in the second half of 2026. "People living

    3/30/26 8:30:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Horn Howard

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    4/2/26 6:19:58 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Boyages Steven Constantine

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:35 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Hurd Jonathan Scott

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:31 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Leadership Updates

    Live Leadership Updates

    View All

    Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

    NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions. "We thank Tom for his 14 years of impactful contributions to Ultragenyx, including transformative business deals that helped build the largest clinical pipeline in rare disease; expanded our reach to patients with fatty acid oxidation diseases, X-linked hypophosphatemia, o

    9/30/25 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Divis

    7/28/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ATHX
    $BIO
    $BIOC
    $EIGR
    Financials

    Live finance-specific insights

    View All

    Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, March 24, 2026: U.

    2/24/26 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market ado

    2/12/26 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and

    2/12/26 4:01:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care